CMKLR1 and neoplasm: They are highly constrained yet highly active and thus represent promising new therapeutic modalities to directly counteract tumor-induced immune evasion or by shuttling cytotoxic cargoes into tumor cells that express CMKLR1 as recently shown for prostate cancer cells [20].